During the past decade, Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 14 clinical trials were completed, i.e. on average, 56% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 5 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" #1 sponsor was "Hoffmann-La Roche" with 18 trials, followed by "Amgen" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Cellectar Biosciences, Inc." with 1 trials sponsored and "Gemin X" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "Jazz Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are "Non-Small Cell Lung Cancer" (9 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Non Small Cell Lung Cancer" (3 trials), "Non-small Cell Lung Cancer" (3 trials) and "Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" in a lesser frequency.

Most popular intervention types in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are "Drug" (33 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (13 trials), "Carboplatin" (9 trials), "Docetaxel" (9 trials), "Gemcitabine" (5 trials) and "Pemetrexed" (5 trials). Other intervention names were less common.

The vast majority of trials in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, 3 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".